Estriol succinate | CAS# 514-68-1 (succinate) | estrogen medication

MedKoo Cat#: 414548 | Name: Estriol succinate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Estriol succinate is an estrogen ester, specifically, an ester of estriol, and acts as a prodrug of estriol in the body. It is described as a weak estrogen in comparison to estradiol valerate. Estriol succinate is used medically via oral and vaginal routes similarly. In estriol succinate, two of the hydroxyl groups of estriol, those at the C16α and C17β positions, are esterified with succinic acid.

Chemical Structure

Estriol succinate

CAS#514-68-1 (succinate)

Theoretical Analysis

MedKoo Cat#: 414548

Name: Estriol succinate

CAS#: 514-68-1 (succinate)

Chemical Formula: C26H32O9

Exact Mass: 488.2046

Molecular Weight: 488.53

Elemental Analysis: C, 63.92; H, 6.60; O, 29.47

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

514-68-1 (succinate) 50-27-1 (free base)

Synonym

Estriol succinate; Estrioli succinas; Oestriol succinate

IUPAC/Chemical Name

4,4'-(((8R,9S,13S,14S,16R,17R)-3-hydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-16,17-diyl)bis(oxy))bis(4-oxobutanoic acid)

InChi Key

VBRVDDFOBZNCPF-BRSFZVHSSA-N

InChi Code

InChI=1S/C26H32O9/c1-26-11-10-17-16-5-3-15(27)12-14(16)2-4-18(17)19(26)13-20(34-23(32)8-6-21(28)29)25(26)35-24(33)9-7-22(30)31/h3,5,12,17-20,25,27H,2,4,6-11,13H2,1H3,(H,28,29)(H,30,31)/t17-,18-,19+,20-,25+,26+/m1/s1

SMILES Code

C[C@]12CC[C@H]3[C@H]([C@@H]1C[C@H]([C@@H]2OC(CCC(O)=O)=O)OC(CCC(O)=O)=O)CCc4c3ccc(O)c4

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 488.53 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: VAN VEENJ. LE SUCCINATE D'OESTRIOL DANS LE TRAITEMENT DES DIATH'ESES H'EMORRAGIQUES [ESTRIOL SUCCINATE IN THE TREATMENT OF HEMORRHAGIC DIATHESES]. Hormoner. 1963;16:1-15. French. PMID: 14064055. 2: Lee JA, Damianov A, Lin CH, Fontes M, Parikshak NN, Anderson ES, Geschwind DH, Black DL, Martin KC. Cytoplasmic Rbfox1 Regulates the Expression of Synaptic and Autism-Related Genes. Neuron. 2016 Jan 6;89(1):113-28. doi: 10.1016/j.neuron.2015.11.025. Epub 2015 Dec 10. PMID: 26687839; PMCID: PMC4858412. 3: Zhu H, Zhang W, Zhao Y, Shu X, Wang W, Wang D, Yang Y, He Z, Wang X, Ying Y. GSK3β-mediated tau hyperphosphorylation triggers diabetic retinal neurodegeneration by disrupting synaptic and mitochondrial functions. Mol Neurodegener. 2018 Nov 22;13(1):62. doi: 10.1186/s13024-018-0295-z. PMID: 30466464; PMCID: PMC6251088. 4: Punnonen R, Söderström KO. The effect of oral estriol succinate therapy on the endometrial morphology in postmenopausal women: the significance of fractionation of the dose. Eur J Obstet Gynecol Reprod Biol. 1983 Jan;14(4):217-24. doi: 10.1016/0028-2243(83)90263-0. PMID: 6832445. 5: Lauritzen C. Results of a 5 years prospective study of estriol succinate treatment in patients with climacteric complaints. Horm Metab Res. 1987 Nov;19(11):579-84. doi: 10.1055/s-2007-1011886. PMID: 3428874. 6: Cabrera J, Canahuate E, del Campo SL, Poloni O, Ramírez SI. Respuesta citológica de la vagina irradiada al succinato de estriol [Cytologic response of the irradiated vagina to estriol succinate]. Rev Chil Obstet Ginecol. 1993;58(4):317-22. Spanish. PMID: 7991851. 7: Yang TS, Tsan SH, Chang SP, Ng HT. Efficacy and safety of estriol replacement therapy for climacteric women. Zhonghua Yi Xue Za Zhi (Taipei). 1995 May;55(5):386-91. PMID: 7641124. 8: Ueno M. [Microglia in Brain Development]. Brain Nerve. 2017 Sep;69(9):985-997. Japanese. doi: 10.11477/mf.1416200858. PMID: 28900061. 9: Berger A, Meissl G. Klinische Erfahrungen mit Ostriolsuccinat bei handchirurgischen Eingriffen [Clinical experiences with estriol succinate in surgery of the hand]. Wien Klin Wochenschr. 1970 Aug 14;82(33):582-3. German. PMID: 5514325. 10: Romero-Salinas, Quiróz-Jiménez. El succinato de estriol y su efecto sobre la contractilidad del útero humano durante el climaterio [Estriol succinate and its effect on the contractility of the human uterus during the climateric]. Ginecol Obstet Mex. 1978 Apr;43(258):269-78. Spanish. PMID: 689426.